BCM
RARE icon

BlueCrest Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlueCrest Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,914
Closed -$480K – 908
2019
Q1 		$480K Buy
+6,914
New +$395K 0.02% 509

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlueCrest Capital Management's RARE Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 6,914 shares — an estimated $480K sold.

BlueCrest Capital Management first reported a position in RARE in Q1 2019 and held it in 1 quarter. The position peaked at $480K in Q1 2019. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 6,914 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $480K.
  • BlueCrest Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Ultragenyx Pharmaceutical position peaked at $480K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.